Infections that had exhausted conventional medicine found new life in an old idea
In the long struggle between human medicine and bacterial adaptation, a team of Israeli researchers has offered a striking reminder that old ideas sometimes outlast the certainties that displaced them. At the Israeli Phage Therapy Center, sixteen patients whose infections had exhausted every available antibiotic were treated with PASA16, a bacteriophage targeting the resilient pathogen Pseudomonas aeruginosa — and thirteen of them recovered. The study, the largest of its kind, does not claim to have solved the antibiotic resistance crisis, but it quietly insists that the answer may have been waiting in nature all along.
- Sixteen patients arrived carrying infections that modern medicine had already failed — bacteria so resistant and so entrenched that conventional treatment had been formally abandoned.
- Pseudomonas aeruginosa, the pathogen at the center of these cases, is a hospital predator that wraps itself in protective biofilms and exploits the vulnerable, making it one of the most feared drug-resistant threats in clinical settings.
- Researchers at Hadassah Hebrew University Medical Center administered the PASA16 phage through multiple routes — intravenous, topical, and direct — tailoring delivery to wherever each infection had taken hold.
- Thirteen of fifteen evaluable patients achieved favorable outcomes, an 86.6% success rate that is extraordinary precisely because it was achieved where antibiotics had already lost.
- With minimal side effects and treatment courses as short as two weeks, the trial now stands as the strongest case yet for moving phage therapy from compassionate use into formal, large-scale clinical trials.
Sixteen patients arrived at the Israeli Phage Therapy Center carrying infections that antibiotics could no longer touch. The culprit was Pseudomonas aeruginosa — a pathogen that thrives in hospitals, shields itself in biofilms, and targets those whose immune systems are already compromised. For these patients, conventional medicine had run out of answers, and the only remaining option was an old idea being carefully revived: using viruses to kill bacteria.
The study, led by Prof. Ran Nir-Paz at Hadassah Hebrew University Medical Center and Prof. Ronen Hazan of the Hebrew University's Faculty of Dental Medicine, was the largest clinical effort to date using a single phage — PASA16 — on a compassionate use basis. Each patient's bacterial isolate was tested for sensitivity before treatment began. The phage was then delivered once or twice daily for periods ranging from eight days to six weeks, through whichever routes the infection required. Most patients had osteoarticular infections or complications tied to implanted medical devices. The phage itself was supplied at no cost by Adaptive Phage Therapeutics, an American company.
The results were striking. Thirteen of the fifteen patients with complete clinical data achieved favorable outcomes — an 86.6% success rate against infections that had already defeated standard treatment. Side effects were minor and manageable throughout.
Neither researcher overstated the findings. This was not a randomized controlled trial, and they said so plainly. But it was the largest series of its kind, and the clarity of the results pointed unmistakably toward the next step: formal clinical trials and the slow, careful work of transforming compassionate use into approved treatment.
The broader significance lies in what the study suggests about medicine's direction. Phage therapy fell out of favor in the West when antibiotics arrived in the mid-twentieth century, but it never vanished — it persisted in Eastern Europe and the former Soviet Union while resistance quietly mounted elsewhere. Now, with antibiotic resistance spreading globally, the approach is being revived with modern rigor. Thirteen patients have their lives back. The question now is how many more might follow.
Sixteen patients arrived at the Israeli Phage Therapy Center carrying infections that antibiotics could no longer touch. These were not routine cases—they were the ones that had exhausted conventional medicine, the persistent bacterial invasions that had resisted drug after drug. The bacteria in question was Pseudomonas aeruginosa, a cunning pathogen that thrives in hospitals, forms protective biofilms around itself, and preys on people whose immune systems are already compromised. For these patients, there was nowhere left to turn except toward an old idea being revived: using viruses to kill bacteria.
The study, led by Prof. Ran Nir-Paz at Hadassah Hebrew University Medical Center and Prof. Ronen Hazan of the Hebrew University's Faculty of Dental Medicine, represented the largest clinical effort to date using a single phage—PASA16—to treat these stubborn infections on a compassionate basis. Phage therapy works on a principle as old as the microscope: bacteriophages are viruses that naturally hunt and destroy bacteria, and they do so with a specificity that antibiotics sometimes lack. The researchers tested each patient's bacterial isolate beforehand to confirm sensitivity to PASA16, then administered the phage through multiple routes—intravenously, directly to infection sites, and topically—depending on where the infection had taken hold. Most patients had osteoarticular infections or infections associated with foreign devices implanted in their bodies.
The treatment regimens were brief by medical standards. Patients received the phage once or twice daily for periods ranging from eight days to six weeks, with most completing their course in roughly two weeks. The phage itself was provided at no cost by Adaptive Phage Therapeutics, an American company, making this a true compassionate use trial—treatment offered to people with nowhere else to go, with minimal expectation of profit. During treatment, only minor side effects emerged, and they were manageable. Thirteen of the fifteen patients with complete clinical data achieved what the researchers called a favorable outcome. That translated to an 86.6% success rate—a figure that would be remarkable in any context, but extraordinary given that these were infections that had already defeated conventional medicine.
Pseudomonas aeruginosa is not an exotic pathogen. It lives in soil, in water, in plants, and even in the human body as a harmless resident. But it becomes dangerous when it finds a host with a weakened immune system or an open wound, a catheter, or a ventilator. In hospitals, it is one of the most common causes of acquired infection, particularly among the most vulnerable patients. The bacteria's ability to form biofilms—slimy, protective communities that shield individual cells from antibiotics—makes it especially difficult to treat. Standard practice often requires combining multiple antibiotics, and even then, success is not guaranteed. For patients like those in this study, the infection had become chronic, resistant, and life-threatening.
Prof. Nir-Paz described the findings as offering hope for patients with persistent infections and highlighting phage therapy's potential as an alternative to conventional antibiotics in the fight against resistant pathogens. Prof. Hazan echoed the sentiment, emphasizing that the 86.6% success rate underscored phage therapy's promise as a tool against antibiotic-resistant bacteria. Neither researcher overstated the case—this was a compassionate use series, not a randomized controlled trial. But it was the largest of its kind, and the results were clear enough to warrant the next step: formal clinical trials and broader exploration of phage therapy as a complementary approach to antibiotic treatment.
What makes this study significant is not just the success rate, but what it suggests about the future of infection treatment. As antibiotic resistance spreads globally, the medical world has been forced to reconsider older approaches. Phage therapy fell out of favor in the West after antibiotics arrived in the mid-twentieth century, but it never disappeared entirely—it remained in use in Eastern Europe and the Soviet Union, where researchers continued to develop it. Now, as resistance mounts, the approach is being revived with modern clinical rigor. This study of sixteen patients with nowhere else to turn has become evidence that the old idea might work. The next phase will be larger trials, standardized protocols, and the slow, careful work of moving from compassionate use to approved treatment. For now, thirteen patients have their lives back.
Citações Notáveis
This groundbreaking research offers hope for patients with persistent infections and highlights the potential of phage therapy as a valuable alternative to conventional antibiotics in combating antibiotic-resistant pathogens.— Prof. Ran Nir-Paz, Israeli Phage Therapy Center
The study's 86.6% success rate offers hope for patients with persistent infections and underscores the potential of phage therapy as an alternative to combat antibiotic-resistant pathogens.— Prof. Ronen Hazan, Hebrew University of Jerusalem
A Conversa do Hearth Outra perspectiva sobre a história
Why does this matter? We have antibiotics. Why do we need viruses to kill bacteria?
Because the bacteria are winning. Pseudomonas aeruginosa has learned to resist most of the drugs we throw at it, especially in hospital settings where it spreads easily. For these sixteen patients, antibiotics had already failed. They were out of options.
So phage therapy is a last resort?
It was, for these patients. But the point of this study is to show it might not have to be. If we can prove it works reliably, it could become a standard tool—not instead of antibiotics, but alongside them, especially for resistant infections.
How does a virus kill bacteria without harming the patient?
Bacteriophages are incredibly specific. They evolved to attack particular bacteria, so they don't touch human cells. The patient's immune system is already dealing with the infection; the phage just tips the balance. And in this study, the side effects were minor and manageable.
What surprised you most about the results?
The speed and the simplicity. Most patients were treated in about two weeks with once or twice daily doses. And thirteen out of fifteen got better. That's not a small number for infections that had already defeated conventional medicine.
What happens next?
Formal clinical trials. This was compassionate use—treatment for people with nowhere else to go. Now researchers need to test it more rigorously, in larger groups, with standardized protocols. If those trials work, phage therapy could become a real option for hospitals dealing with resistant infections.